Introduction: eventually resistance to treatment in more than 70 years. percentage of
patients. Ther Ovarian cancer is one of the most deadly malignancies in women. Over time,
tumors show resistance to these chemotherapy compounds and cause tumor recurrence and
efore, identifying people without response can be an important step towards increasing the
survival of patients with ovarian cancer. Therefore, determining potential indicators such as
specific biomarkers predicting platinum treatment response, which can help clinical
decisions and improve prognosis, can be of vital importance.
Methods: In this study, 50 tissue samples from patients with ovarian cancer
after chemotherapy and platinum-based treatment and 50 healthy tissue samples were
collected and selected as the control group, then DNA extraction of the samples was
performed using a special kit and in The continuation of SLCSA gene polymorphism was
investigated by Tetra-ARMS PCR technique
Results: Results: In patients, 11 cases (22%) had GG genotype (wild homozygous), 5 cases (10%)
had GA genotype (heterozygous) and 34 cases (68%) had AA genotype (mutant
homozygous). Also, in the control subjects, 38 cases (76%) had GG genotype (wild
homozygous), 5 cases (10%) had GA genotype (heterozygous) and 7 cases (14%) had AA
genotype (mutant homozygous). The obtained results showed that the frequency of the
wild G allele was 27% and the frequency of the mutant A allele was 73% in the patient
group. There is a significant difference between the control group and the control group in
terms of target polymorphism (p<0.05).
Conclusion: Conclusion: The present study showed that SLC5A polymorphism is associated with
ovarian cancer and can be used as a biomarker in the prognosis of platinum drug use.